AZ gets rights to candidate heart drug

Sunday 16 January 2022
Country

United Kingdom

AstraZeneca Plc has negotiated rights to an early clinical stage therapeutic designed to remove amyloid fibril deposits in the heart. The agreement, with Neurimmune AG of Switzerland, relates to NI006, a monoclonal antibody in Phase 1b for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a systemic condition that can lead to progressive heart failure.